

**We are inviting you, as a patient recently diagnosed with early-stage breast cancer, to participate in a research study that aims to improve treatment decision-making through an innovative artificial intelligence–clinical decision support system (AI-CDSS). This tool is designed to generate personalized recurrence risk predictions to help guide your treatment choices.**

**Why have I been invited?**

You have been invited because you meet the eligibility criteria as a newly diagnosed early-stage breast cancer patient considering various treatment options. Your participation will help assess whether the AI-CDSS enhances the treatment planning process and supports improved patient outcomes.

**Do I have to take part?**

Participation in this study is entirely voluntary. You may choose not to participate or withdraw at any time without any impact on your treatment or your relationship with Tri-Service General Hospital.

**What will happen if I take part?**

If you agree to participate, you will be randomly assigned to one of two groups. One group will have their treatment consultation enhanced by the AI-CDSS, where your clinician will use the system to generate a personalized risk prediction for breast cancer recurrence and discuss tailored treatment recommendations with you. The other group will receive standard treatment planning without the AI tool. In both groups, you will complete questionnaires at baseline (before your consultation) and at 1, 3, and 6 months afterward to evaluate your satisfaction, understanding of recurrence risk, decisional clarity, and overall quality of life.

**Are there any expenses or payment involved?**

There is no payment for participating in this study; however, any expenses incurred as a result of your participation will be reimbursed.

**Confidentiality**

All information you provide will be kept strictly confidential and used solely for research purposes. Your identity will be protected in any reports or publications.

**Study Location**

This study is being conducted at Tri-Service General Hospital. The results may contribute to improvements in breast cancer treatment planning and shared

decision-making processes in the future.

**Interested?**

If you are interested in participating or have any questions about the study, please contact the study coordinator using the details below. Thank you for considering this opportunity to contribute to research that may enhance breast cancer care.

---

**Contact Details:**

Name: Dr. Hung-Sheng Shang

Email: [iamkeith@mail.ndmctsgh.edu.tw](mailto:iamkeith@mail.ndmctsgh.edu.tw)

Phone: +886 920713130

Address: No. 325, Sec. 2, Chenggong Rd., Neihu Dist., Taipei City, Taiwan, 114202